Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selection of a novel cell-internalizing RNA aptamer specific for CD22 antigen in B cell acute lymphoblastic leukemia

27 Jul 2023

Abstract excerpt

Despite improvements in B cell acute lymphoblastic leukemia (B-ALL) treatment, a significant number of patients experience relapse of the disease, resulting in poor prognosis and high mortality. One of the drawbacks of current B-ALL treatments is the high toxicity associated with the non-specificity of chemotherapeutic drugs. Targeted therapy is an appealing strategy to treat B-ALL to mitigate these toxic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Advanced biosensing and bioanalysis techniques
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37662970
DOI: 10.1016/j.omtn.2023.07.028

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selection of a novel cell-internalizing RNA aptamer specific for CD22 antigen in B cell acute lymphoblastic leukemiaPMID 37662970Read ↗

Improved Aptamers for the Diagnosis and Potential Treatment of HER2-Positive CancerSemantic proximity Read ↗

Isolation of RNA Aptamers Targeting HER-2-overexpressing Breast Cancer Cells Using Cell-SELEXSemantic proximity Read ↗

Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemiaSemantic proximity Read ↗

Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicinSemantic proximity Read ↗

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.Semantic proximity Read ↗

A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALLSemantic proximity Read ↗

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALLSemantic proximity Read ↗

Targeting Chronic Lymphocytic Leukemia With DNA NanoparticlesSemantic proximity Read ↗

The biochemical function of bivalent aptamer assemblies against B-cell markers CD19 and CD20Semantic proximity Read ↗

CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Targeting Insulin Receptor with a Novel Internalizing AptamerSemantic proximity Read ↗

Aptamers Against Cell Surface Receptors: Selection, Modification and ApplicationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.